| scholarly article | Q13442814 |
| P50 | author | Gordon J. Freeman | Q27088375 |
| Rafi Ahmed | Q29017279 | ||
| Sang-Jun Ha | Q37368920 | ||
| Scott N. Mueller | Q39678898 | ||
| Arlene Sharpe | Q58235901 | ||
| E. John Wherry | Q88954779 | ||
| P2093 | author name string | Daniel L Barber | |
| Rachael D Aubert | |||
| P2860 | cites work | PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion | Q27477628 |
| Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression | Q27478366 | ||
| Interleukin-10 determines viral clearance or persistence in vivo | Q27486832 | ||
| Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
| PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression | Q29618956 | ||
| Immunology of hepatitis B virus and hepatitis C virus infection | Q29618957 | ||
| Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity | Q33186765 | ||
| Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination | Q33884084 | ||
| Memory CD8 T-cell differentiation during viral infection | Q34152220 | ||
| Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction | Q34570127 | ||
| PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection | Q34570624 | ||
| PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors | Q34574649 | ||
| Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection | Q34619603 | ||
| Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection | Q34712708 | ||
| Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment | Q34857689 | ||
| Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination | Q35857708 | ||
| SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection | Q35901710 | ||
| Resolution of a chronic viral infection after interleukin-10 receptor blockade | Q36228023 | ||
| Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection | Q36229254 | ||
| T cells and viral persistence: lessons from diverse infections | Q36238129 | ||
| Therapeutic vaccination against chronic hepatitis B virus infection | Q36388320 | ||
| Therapeutic vaccination for chronic infectious diseases: lessons from HIV-1. | Q36388405 | ||
| IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection | Q36509838 | ||
| Recent development of therapeutics for chronic HCV infection | Q36530947 | ||
| Antigen-independent memory CD8 T cells do not develop during chronic viral infection | Q37591855 | ||
| Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. | Q38319280 | ||
| Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells | Q39606948 | ||
| A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. | Q40547706 | ||
| Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection | Q40594636 | ||
| Vaccination to treat persistent viral infection | Q41723256 | ||
| HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory | Q42258606 | ||
| Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection | Q42797242 | ||
| Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa | Q42977701 | ||
| Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. | Q42981482 | ||
| Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence | Q43032677 | ||
| Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection | Q43036301 | ||
| Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. | Q43048494 | ||
| Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha | Q43513123 | ||
| Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression | Q45732561 | ||
| Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection | Q45746042 | ||
| Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. | Q45769787 | ||
| Distinct mechanisms control human naive and antigen-experienced CD8+ T lymphocyte proliferation. | Q51985047 | ||
| Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. | Q52010404 | ||
| Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. | Q53663784 | ||
| Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques | Q57089576 | ||
| Regulation of Homeostatic Chemokine Expression and Cell Trafficking During Immune Responses | Q57227496 | ||
| Accumulation of dysfunctional effector CD8+T cells in the liver of patients with chronic HCV infection | Q57235899 | ||
| B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B | Q80257446 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 543-555 | |
| P577 | publication date | 2008-03-10 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection | |
| P478 | volume | 205 |
| Q35502650 | 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection |
| Q40211951 | A new vaccination strategy to trigger specific CD4 T-cell response in chronic viral infection |
| Q90702649 | A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial |
| Q42140400 | A siege of hepatitis: immune boost for viral hepatitis |
| Q35695370 | ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy |
| Q33882896 | Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis |
| Q37111511 | An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1 |
| Q41242778 | An optimized peptide vaccine strategy capable of inducing multivalent CD8(+) T cell responses with potent antitumor effects |
| Q33489565 | Anatomy of viral persistence |
| Q40150431 | Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle. |
| Q33887812 | Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens |
| Q36510860 | Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens |
| Q35666506 | Beyond adjuvants: immunomodulation strategies to enhance T cell immunity |
| Q34034408 | Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma |
| Q90207349 | CD28 family of receptors inter-connect in the regulation of T-cells |
| Q35861968 | CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells |
| Q36951532 | CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease |
| Q39218899 | CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway |
| Q36677821 | CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptor. |
| Q35085469 | Characteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients |
| Q90479796 | Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection |
| Q53333415 | Cloning and identification of porcine programmed death 1. |
| Q39761212 | Co-inhibitory molecules: Controlling the effectors or controlling the controllers? |
| Q64063958 | Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy |
| Q42992408 | Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice |
| Q34891171 | Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. |
| Q36919711 | Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease |
| Q27490355 | Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C |
| Q40144211 | Culling of APCs by inflammatory cell death pathways restricts TIM3 and PD-1 expression and promotes the survival of primed CD8 T cells |
| Q35329213 | Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade |
| Q38709894 | De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation |
| Q34626030 | Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response. |
| Q59359697 | Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand |
| Q34982085 | Dendritic cell control of tolerogenic responses |
| Q34072838 | Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection |
| Q93090012 | Differential genetic and functional background in inflammatory bowel disease phenotypes of a Greek population: a systems bioinformatics approach |
| Q55365295 | Differentiation and Function of Follicular CD8 T Cells During Human Immunodeficiency Virus Infection. |
| Q37548125 | Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection |
| Q34320284 | Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection |
| Q53278564 | Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection. |
| Q40295337 | Efficient control of chronic LCMV infection by a CD4 T cell epitope-based heterologous prime-boost vaccination in a murine model |
| Q34310880 | Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome |
| Q34033862 | Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice |
| Q34105724 | Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection. |
| Q35082215 | Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection |
| Q35329825 | Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma |
| Q38239285 | FcγRIIB as a key determinant of agonistic antibody efficacy |
| Q33941340 | Features of responding T cells in cancer and chronic infection. |
| Q34856800 | Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells |
| Q34514517 | Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses |
| Q37329003 | HIV infection: what should be considered in approaches for a cure? |
| Q37208927 | High antigen levels are the cause of T cell exhaustion during chronic viral infection |
| Q37123414 | High production rates sustain in vivo levels of PD-1high simian immunodeficiency virus-specific CD8 T cells in the face of rapid clearance |
| Q37374676 | Highly efficient antiviral CD8+ T-cell induction by peptides coupled to the surfaces of liposomes |
| Q37068471 | IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection |
| Q36509838 | IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection |
| Q35801754 | IL-4 Induced Innate CD8+ T Cells Control Persistent Viral Infection. |
| Q38845026 | Immune checkpoints and their inhibition in cancer and infectious diseases. |
| Q37406571 | Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques |
| Q44082596 | Immune-based therapy for chronic hepatitis C. |
| Q37767587 | Immunity and immunopathology to viruses: what decides the outcome? |
| Q34291105 | Immunization with Different Viral Antigens Alters the Pattern of T Cell Exhaustion and Latency in Herpes Simplex Virus Type 1-Infected Mice |
| Q59098671 | Immunology and the elusive AIDS vaccine |
| Q51898059 | Immunosuppressive mechanisms during viral infectious diseases. |
| Q37173264 | Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). |
| Q37157206 | Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection |
| Q33753964 | In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein |
| Q37766241 | Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. |
| Q54202082 | Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. |
| Q44473477 | Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis |
| Q36109361 | Innate IFN-γ is essential for programmed death ligand-1-mediated T cell stimulation following Listeria monocytogenes infection |
| Q47563901 | Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome? Neoantigens as Vaccine Targets for Cancer |
| Q96124007 | Lentiviral-Vector-Based Dendritic Cell Vaccine Synergizes with Checkpoint Blockade to Clear Chronic Viral Infection |
| Q35895721 | Long noncoding RNA derived from CD244 signaling epigenetically controls CD8+ T-cell immune responses in tuberculosis infection |
| Q33539383 | Making antigen invisible: a coinhibitory molecule regulates the interaction between T cells and dendritic cells |
| Q38098681 | Manipulating the PD-1 pathway to improve immunity |
| Q35659317 | Memory CD8 T cell transcriptional plasticity |
| Q36018535 | Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help |
| Q33395512 | Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis |
| Q27022761 | Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer |
| Q36211501 | Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. |
| Q41181556 | Multifarious immunotherapeutic approaches to cure HIV-1 infection |
| Q58861232 | Mycobacterium tuberculosis Promotes Regulatory T-Cell Expansion via Induction of Programmed Death-1 Ligand 1 (PD-L1, CD274) on Dendritic Cells |
| Q34845501 | Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8⁺ T-cell exhaustion. |
| Q36072424 | Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. |
| Q38180981 | New therapeutic vaccination strategies for the treatment of chronic hepatitis B. |
| Q37130191 | Next generation protein based Streptococcus pneumoniae vaccines |
| Q64229705 | Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens |
| Q33938039 | Opposing positive and negative regulation of T cell activity during viral persistence |
| Q37469795 | PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention |
| Q34325908 | PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model |
| Q36750008 | PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis |
| Q33866996 | PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells |
| Q37479650 | PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis. |
| Q36220691 | PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines |
| Q36890941 | PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells |
| Q42017650 | PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. |
| Q56891292 | PD-L1, TIM-3, and CTLA-4 blockade fail to promote resistance to secondary infection with virulent strains of |
| Q36887608 | PDL1 Regulation by p53 via miR-34 |
| Q38105994 | Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-γ-mediated CD8(+) T cell cytotoxicity |
| Q38265356 | Peptide-MHC multimer-based monitoring of CD8 T-cells in HIV-1 infection and AIDS vaccine development |
| Q37415520 | Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease |
| Q39432561 | Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis |
| Q36478253 | Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. |
| Q37316915 | Programmed death-1 expression is associated with the disease status in hepatitis B virus infection |
| Q37728651 | Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer |
| Q90220049 | Re-defining T-Cell Exhaustion: Subset, Function, and Regulation |
| Q37700859 | Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection |
| Q37686978 | Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway |
| Q33332291 | Resisting immune exhaustion in HIV-1 infection. |
| Q35140996 | Responsiveness of HIV-specific CD4 T cells to PD-1 blockade |
| Q90243326 | Restoring, releasing or replacing adaptive immunity in chronic hepatitis B |
| Q52719531 | Role of PD-1 during effector CD8 T cell differentiation. |
| Q24634293 | Role of PD-1 in HIV pathogenesis and as target for therapy |
| Q41087941 | Roles of the programmed cell death 1, T cell immunoglobulin mucin-3, and cluster of differentiation 288 pathways in the low reactivity of invariant natural killer T cells after chronic hepatitis B virus infection |
| Q42232110 | Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice |
| Q36937145 | Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade |
| Q29620463 | T cell exhaustion |
| Q37940960 | The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion |
| Q38734257 | The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them |
| Q35193019 | The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism |
| Q36005107 | The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells |
| Q38075327 | The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses |
| Q36380567 | The role of IL-10 in regulating immunity to persistent viral infections |
| Q37309250 | Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. |
| Q33614649 | Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion |
| Q46428828 | Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection. |
| Q33835488 | Update on animal models for HIV research |
| Q33475710 | siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals |
Search more.